Preliminary

ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R mutations in KRASAs of the April 25, 2023 data cut-off date, among the 22 evaluable patients, preliminary data from the trial…

- Grew Q2 2023 Preliminary Revenue 18% and Preliminary Adjusted EBITDA 23% vs. Q2 2022 - - Evaluating Programs to Cull Approximately 10% of the Corporate Portfolio - SCOTTSDALE, Ariz., Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Joint Corp.…

Following improved business performance in Q2 and H1 2023, NNIT upgrades the full-year outlook and now expects to generate revenue growth of around 15% and an operating profit margin before special items of around 6% in 2023 against the…

SEATTLE, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for cancers, today announced it will unveil preliminary best-in-class data from an ongoing…

Preliminary Second Quarter Highlights Revenue of $272.9 million, up 2.3% year-over-year (up 2.5% on a constant currency basis)Net loss of $30.9 millionGross profit(1) of $60.9 million, up 23.0% or $11.4 million year-over-year, with a…

Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01…

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced the acceptance of four abstracts for poster presentation at the European Society for Medical Oncology (ESMO)…

Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage…

Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses (PR) and seven patients with prolonged stable disease (SD) Efficacy and tolerability data from dose escalation and expansion results inform…

CHARLOTTE, NC, May 24, 2023 (GLOBE NEWSWIRE) -- Strong Global…